H-Gamma1 Heavy Chain Anti-Cd47 (1-444), G1V92-1 Vh E44, Ch1 E77 [Vh E44 (Homo Sapiens Ighv1-46*01 (87.6%) Q44>E (39') -(Ighd) -Ighj4*01 (100%), Cdr-Imgt [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 E77, G1V93 Ch1 C12, G1V37 H S5, G1V74 Ch3 C10, G1V32 Ch3 W22 (Knob) (Ch1 K12>C (130), G77>E (163), K120 (211) (115-212), Hinge 1-15 C5>S (217) (213-227), Ch2 (228-337), Ch3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), Chs (443-444)) (115-444)], (130-209')- Disulfide With L-Kappa Light Chain Anti-Cd47 (1'-214') Kv92-1 V-Kappa K44, C-Kappa K3 [V-Kappa K44 (Homo Sapiens Igkv3-20*01 (83.3%) Q44>K (38') -Igkj1*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (98.1%) Km3 A45.1, V101, K3, Kcv37 C121, S126 (C-Kappa S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-Gamma1 Heavy Chain Anti-Cldn18 (1-449), G1V92-2 Vh K44, Ch1 K77 [Vh K44 (Homo Sapiens Ighv3-48*01 (87.8%) Q44>K (39'') -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 K77, G1V75 Ch3 C5, G1V33 Ch3 S22, A24, V86 (Hole) (Ch1 G77>K (168''), K120 (216'') (120''-217''), Hinge 1-15 (218''-232''), Ch2 (233''-342''), Ch3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), Chs (448''-449'')) (120''-449'')], (222''-220''')-Disulfide With L-Kappa Light Chain Anti-Cldn18 (1'''-220''') Kv92-2 V-Kappa E44, C-Kappa E3 [V-Kappa E44 (Musmus/Homsap (Mus Musculus Igkv8-19*01 (79.2%) Q44>E (44''') -Igkj2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo Sapiens Igkv1-39*01 (78.2%) Q44>E (44''') -Igkj1*01 (100%), Cdr -Imgt [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo Sapiens Igkc*01 (99.1%) Km3 A45.1, V101, E3 (C-Kappa S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; Dimer (223-228'':226-231'':351-351'')-Trisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Biliary Tract Cancer
Explore 83 assets in Biliary Tract Cancer →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Phanes Therapeutics
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05482893CT.gov Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Biliary Tract Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| H-Gamma1 Heavy Chain Anti-Cd47 (1-444), G1V92-1 Vh E44, Ch1 E77 [Vh E44 (Homo Sapiens Ighv1-46*01 (87.6%) Q44>E (39') -(Ighd) -Ighj4*01 (100%), Cdr-Imgt [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 E77, G1V93 Ch1 C12, G1V37 H S5, G1V74 Ch3 C10, G1V32 Ch3 W22 (Knob) (Ch1 K12>C (130), G77>E (163), K120 (211) (115-212), Hinge 1-15 C5>S (217) (213-227), Ch2 (228-337), Ch3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), Chs (443-444)) (115-444)], (130-209')- Disulfide With L-Kappa Light Chain Anti-Cd47 (1'-214') Kv92-1 V-Kappa K44, C-Kappa K3 [V-Kappa K44 (Homo Sapiens Igkv3-20*01 (83.3%) Q44>K (38') -Igkj1*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (98.1%) Km3 A45.1, V101, K3, Kcv37 C121, S126 (C-Kappa S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-Gamma1 Heavy Chain Anti-Cldn18 (1-449), G1V92-2 Vh K44, Ch1 K77 [Vh K44 (Homo Sapiens Ighv3-48*01 (87.8%) Q44>K (39'') -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 K77, G1V75 Ch3 C5, G1V33 Ch3 S22, A24, V86 (Hole) (Ch1 G77>K (168''), K120 (216'') (120''-217''), Hinge 1-15 (218''-232''), Ch2 (233''-342''), Ch3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), Chs (448''-449'')) (120''-449'')], (222''-220''')-Disulfide With L-Kappa Light Chain Anti-Cldn18 (1'''-220''') Kv92-2 V-Kappa E44, C-Kappa E3 [V-Kappa E44 (Musmus/Homsap (Mus Musculus Igkv8-19*01 (79.2%) Q44>E (44''') -Igkj2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo Sapiens Igkv1-39*01 (78.2%) Q44>E (44''') -Igkj1*01 (100%), Cdr -Imgt [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo Sapiens Igkc*01 (99.1%) Km3 A45.1, V101, E3 (C-Kappa S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; Dimer (223-228'':226-231'':351-351'')-Trisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa (this asset) | Phanes Therapeutics | P1/2 | CC · 47 |
| Cis-Diamminedichloroplatinum Ii | Merck Sharp & Dohme LLC | P3 | BB |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | BB |
| Epirubicin | Merck Sharp & Dohme LLC | P3 | BB |
| Fluorouracilum | Shenzhen Xinhe Biomedical | P2 | B |
| Capecitabine | Zhejiang Cancer Hospital | P2 | B |
| Durvalumab | Replimune, Inc. | P2 | B |
| Datopotamab Deruxtecan | AstraZeneca | P2 | B |
| Oxaliplatin | Zhejiang Cancer Hospital | P1/2 | B |
+42 more in the Biliary Tract Cancer cohort
Other indications for H-Gamma1 Heavy Chain Anti-Cd47 (1-444), G1V92-1 Vh E44, Ch1 E77 [Vh E44 (Homo Sapiens Ighv1-46*01 (87.6%) Q44>E (39') -(Ighd) -Ighj4*01 (100%), Cdr-Imgt [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 E77, G1V93 Ch1 C12, G1V37 H S5, G1V74 Ch3 C10, G1V32 Ch3 W22 (Knob) (Ch1 K12>C (130), G77>E (163), K120 (211) (115-212), Hinge 1-15 C5>S (217) (213-227), Ch2 (228-337), Ch3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), Chs (443-444)) (115-444)], (130-209')- Disulfide With L-Kappa Light Chain Anti-Cd47 (1'-214') Kv92-1 V-Kappa K44, C-Kappa K3 [V-Kappa K44 (Homo Sapiens Igkv3-20*01 (83.3%) Q44>K (38') -Igkj1*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (98.1%) Km3 A45.1, V101, K3, Kcv37 C121, S126 (C-Kappa S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-Gamma1 Heavy Chain Anti-Cldn18 (1-449), G1V92-2 Vh K44, Ch1 K77 [Vh K44 (Homo Sapiens Ighv3-48*01 (87.8%) Q44>K (39'') -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 K77, G1V75 Ch3 C5, G1V33 Ch3 S22, A24, V86 (Hole) (Ch1 G77>K (168''), K120 (216'') (120''-217''), Hinge 1-15 (218''-232''), Ch2 (233''-342''), Ch3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), Chs (448''-449'')) (120''-449'')], (222''-220''')-Disulfide With L-Kappa Light Chain Anti-Cldn18 (1'''-220''') Kv92-2 V-Kappa E44, C-Kappa E3 [V-Kappa E44 (Musmus/Homsap (Mus Musculus Igkv8-19*01 (79.2%) Q44>E (44''') -Igkj2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo Sapiens Igkv1-39*01 (78.2%) Q44>E (44''') -Igkj1*01 (100%), Cdr -Imgt [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo Sapiens Igkc*01 (99.1%) Km3 A45.1, V101, E3 (C-Kappa S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; Dimer (223-228'':226-231'':351-351'')-Trisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastroesophageal Adenocarcinoma | — | P1/2 | CC · 47 |
| Pancreatic Ductal Adenocarcinoma | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. H-Gamma1 Heavy Chain Anti-Cd47 (1-444), G1V92-1 Vh E44, Ch1 E77 [Vh E44 (Homo Sapiens Ighv1-46*01 (87.6%) Q44>E (39') -(Ighd) -Ighj4*01 (100%), Cdr-Imgt [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 E77, G1V93 Ch1 C12, G1V37 H S5, G1V74 Ch3 C10, G1V32 Ch3 W22 (Knob) (Ch1 K12>C (130), G77>E (163), K120 (211) (115-212), Hinge 1-15 C5>S (217) (213-227), Ch2 (228-337), Ch3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), Chs (443-444)) (115-444)], (130-209')- Disulfide With L-Kappa Light Chain Anti-Cd47 (1'-214') Kv92-1 V-Kappa K44, C-Kappa K3 [V-Kappa K44 (Homo Sapiens Igkv3-20*01 (83.3%) Q44>K (38') -Igkj1*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (98.1%) Km3 A45.1, V101, K3, Kcv37 C121, S126 (C-Kappa S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-Gamma1 Heavy Chain Anti-Cldn18 (1-449), G1V92-2 Vh K44, Ch1 K77 [Vh K44 (Homo Sapiens Ighv3-48*01 (87.8%) Q44>K (39'') -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 K77, G1V75 Ch3 C5, G1V33 Ch3 S22, A24, V86 (Hole) (Ch1 G77>K (168''), K120 (216'') (120''-217''), Hinge 1-15 (218''-232''), Ch2 (233''-342''), Ch3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), Chs (448''-449'')) (120''-449'')], (222''-220''')-Disulfide With L-Kappa Light Chain Anti-Cldn18 (1'''-220''') Kv92-2 V-Kappa E44, C-Kappa E3 [V-Kappa E44 (Musmus/Homsap (Mus Musculus Igkv8-19*01 (79.2%) Q44>E (44''') -Igkj2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo Sapiens Igkv1-39*01 (78.2%) Q44>E (44''') -Igkj1*01 (100%), Cdr -Imgt [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo Sapiens Igkc*01 (99.1%) Km3 A45.1, V101, E3 (C-Kappa S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; Dimer (223-228'':226-231'':351-351'')-Trisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa in Biliary Tract Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/h-gamma1-heavy-chain-anti-cd47-1-444-g1v92-1-vh-e44-ch1-e77-vh-e44-homo-sapiens-ighv1-4601-876-q44e-39-ighd-ighj401-100-cdr-imgt-887-26-3351-5897-103-1-114-homo-sapiens-ighg101-g1m171-ch1-k120-ch3-d12-l14-ch1-e77-g1v93-ch1-c12-g1v37-h-s5-g1v74-ch3-c10-g1v32-ch3-w22-knob-ch1-k12c-130-g77e-163-k120-211-115-212-hinge-1-15-c5s-217-213-227-ch2-228-337-ch3-s10c-351-d12-353-l14-355-t22w-363-338-442-chs-443-444-115-444-130-209-disulfide-with-l-kappa-light-chain-anti-cd47-1-214-kv92-1-v-kappa-k44-c-kappa-k3-v-kappa-k44-homo-sapiens-igkv3-2001-833-q44k-38-igkj101-917-cdr-imgt-639-27-3250-5289-97-1-107-homo-sapiens-igkc01-981-km3-a451-v101-k3-kcv37-c121-s126-c-kappa-s3k-114-a451-153-v101-191-f121c-209-c126s-214-108-214-h-gamma1-heavy-chain-anti-cldn18-1-449-g1v92-2-vh-k44-ch1-k77-vh-k44-homo-sapiens-ighv3-4801-878-q44k-39-ighd-ighj401-929-cdr-imgt-8812-26-3351-5897-108-1-119-homo-sapiens-ighg101-g1m171-ch1-k120-ch3-d12-l14-ch1-k77-g1v75-ch3-c5-g1v33-ch3-s22-a24-v86-hole-ch1-g77k-168-k120-216-120-217-hinge-1-15-218-232-ch2-233-342-ch3-y5c-351-d12-358-l14-360-t22s-368-l24a-370-y86v-409-343-447-chs-448-449-120-449-222-220-disulfide-with-l-kappa-light-chain-anti-cldn18-1-220-kv92-2-v-kappa-e44-c-kappa-e3-v-kappa-e44-musmushomsap-mus-musculus-igkv8-1901-792-q44e-44-igkj203-818-s120q-106-l124v-110homo-sapiens-igkv1-3901-782-q44e-44-igkj101-100-cdr-imgt-1239-27-3856-5895-103-1-113-homo-sapiens-igkc01-991-km3-a451-v101-e3-c-kappa-s3e-120-a451-159-v101-197-114-220-dimer-223-228226-231351-351-trisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-glycoform-alfa-biliary-tract-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →